Approval · Notice of Compliance 35706 · 2025
APO-CLARITHROMYCIN: Notice of Compliance 35706
Issued July 22, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35706
- Date
- July 22, 2025
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to The Product Monograph. Update to the Package Insert
- Canadian reference product
- BIAXIN. BIAXIN BD (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-CLARITHROMYCIN | Not yet assigned | — |
| APO-CLARITHROMYCIN XL | Not yet assigned | — |
Medicinal ingredients
- CLARITHROMYCIN 250 MG per TAB
- CLARITHROMYCIN 500 MG per TAB